Morgan Stanley analyst Thibault Boutherin lowered the firm’s price target on Novo Nordisk (NVO) to DKK 550 from DKK 600 and keeps an Equal Weight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- JPMorgan sees ‘most favored nation’ drug order facing ‘significant push back’
- Pharma Stocks Rally despite Trump’s Plan to Cut Drug Prices
- White House publishes Trump executive order aimed at lowering drug prices
- Many patients soon to be forced to switch obesity drug, NYT says
- Eli Lilly’s Zepbound Defeats Novo Nordisk’s Wegovy Once Again